244 related articles for article (PubMed ID: 31638280)
21. Anti-TIF1-γ autoantibodies: warning lights of a tumour autoantigen.
De Vooght J; Vulsteke JB; De Haes P; Bossuyt X; Lories R; De Langhe E
Rheumatology (Oxford); 2020 Mar; 59(3):469-477. PubMed ID: 31883334
[TBL] [Abstract][Full Text] [Related]
22. Genetic background may contribute to the latitude-dependent prevalence of dermatomyositis and anti-TIF1-γ autoantibodies in adult patients with myositis.
Parkes JE; Rothwell S; Oldroyd A; Chinoy H; Lamb JA;
Arthritis Res Ther; 2018 Jun; 20(1):117. PubMed ID: 29884237
[TBL] [Abstract][Full Text] [Related]
23. Serum interferon-α is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis.
Horai Y; Koga T; Fujikawa K; Takatani A; Nishino A; Nakashima Y; Suzuki T; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Ida H; Kakugawa T; Sakamoto N; Ishimatsu Y; Mukae H; Hamaguchi Y; Fujimoto M; Kuwana M; Origuchi T; Kohno S; Kawakami A
Mod Rheumatol; 2015 Jan; 25(1):85-9. PubMed ID: 24716595
[TBL] [Abstract][Full Text] [Related]
24. ELISA, protein immunoprecipitation and line blot assays for anti-TIF1-gamma autoantibody detection in cancer-associated dermatomyositis.
Selickaja S; Galindo-Feria AS; Dani L; Mimori T; Rönnelid J; Holmqvist M; Lundberg IE; Venalis P
Rheumatology (Oxford); 2022 Nov; 61(12):4991-4996. PubMed ID: 35579337
[TBL] [Abstract][Full Text] [Related]
25. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease.
Sato S; Kuwana M; Fujita T; Suzuki Y
Mod Rheumatol; 2013 May; 23(3):496-502. PubMed ID: 22644102
[TBL] [Abstract][Full Text] [Related]
26. The IgG2 Isotype of Anti-Transcription Intermediary Factor 1γ Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis.
Aussy A; Fréret M; Gallay L; Bessis D; Vincent T; Jullien D; Drouot L; Jouen F; Joly P; Marie I; Meyer A; Sibilia J; Bader-Meunier B; Hachulla E; Hamidou M; Huë S; Charuel JL; Fabien N; Viailly PJ; Allenbach Y; Benveniste O; Cordel N; Boyer O;
Arthritis Rheumatol; 2019 Aug; 71(8):1360-1370. PubMed ID: 30896088
[TBL] [Abstract][Full Text] [Related]
27. Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis.
Moghadam-Kia S; Oddis CV; Sato S; Kuwana M; Aggarwal R
Arthritis Care Res (Hoboken); 2016 May; 68(5):689-94. PubMed ID: 26414240
[TBL] [Abstract][Full Text] [Related]
28. A Case in Which Breast Cancer Developed at the Same Time As Dermatomyositis, and the Onset of New Cancer Was Able to Be Predicted by the Exacerbating Skin Symptoms and Parallel Increase in the Anti-TIF1-γ Antibody Levels.
Akagi H; Wada T
Intern Med; 2023; 62(20):3057-3062. PubMed ID: 37839875
[TBL] [Abstract][Full Text] [Related]
29. Elevated serum B-cell activating factor levels in patients with dermatomyositis: Association with interstitial lung disease.
Matsushita T; Kobayashi T; Kano M; Hamaguchi Y; Takehara K
J Dermatol; 2019 Dec; 46(12):1190-1196. PubMed ID: 31631384
[TBL] [Abstract][Full Text] [Related]
30. Development of dermatomyositis after anti-transcriptional intermediary factor 1-γ antibody seroconversion during treatment for small cell lung cancer.
Sato Y; Tanino Y; Nikaido T; Togawa R; Kawamata T; Watanabe N; Sato R; Yamada R; Onuma T; Tomita H; Saito M; Rikimaru M; Morimoto J; Suzuki Y; Minemura H; Saito J; Kanazawa K; Yamada S; Hashimoto Y; Shibata Y
BMC Pulm Med; 2022 May; 22(1):191. PubMed ID: 35549684
[TBL] [Abstract][Full Text] [Related]
31. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis.
Fiorentino DF; Kuo K; Chung L; Zaba L; Li S; Casciola-Rosen L
J Am Acad Dermatol; 2015 Mar; 72(3):449-55. PubMed ID: 25595720
[TBL] [Abstract][Full Text] [Related]
32. Strong correlation between cancer progression and anti-transcription intermediary factor 1γ antibodies in dermatomyositis patients.
Ogawa-Momohara M; Muro Y; Mitsuma T; Katayama M; Yanaba K; Nara M; Kakeda M; Kono M; Akiyama M
Clin Exp Rheumatol; 2018; 36(6):990-995. PubMed ID: 29745874
[TBL] [Abstract][Full Text] [Related]
33. Clinical features and risk factors of lung cancer in elderly patients with dermatomyositis.
Zhou B; Li S; Xie X; Xu S; Li F; Long L
Thorac Cancer; 2023 May; 14(13):1171-1178. PubMed ID: 37042120
[TBL] [Abstract][Full Text] [Related]
34. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis.
Matsushita T; Mizumaki K; Kano M; Yagi N; Tennichi M; Takeuchi A; Okamoto Y; Hamaguchi Y; Murakami A; Hasegawa M; Kuwana M; Fujimoto M; Takehara K
Br J Dermatol; 2017 Feb; 176(2):395-402. PubMed ID: 27452897
[TBL] [Abstract][Full Text] [Related]
35. Clinical features of anti-transcription intermediary factor 1γ (TIF1γ)-positive dermatomyositis with internal malignancy and investigation of the involvement of TIF1γ expression in tumors in the pathogenesis of cancer-associated dermatomyositis.
Motegi SI; Sekiguchi A; Ikeuchi H; Sakairi T; Ogawa H; Fujii T; Sohda M; Yajima T; Ida S; Takayasu Y; Shimoda Y; Hiromura K; Saeki H; Shirabe K; Chikamatsu K; Yokoo H; Oyama T; Ishikawa O
J Dermatol; 2020 Dec; 47(12):1395-1402. PubMed ID: 32734678
[TBL] [Abstract][Full Text] [Related]
36. Use of Anti-transcriptional Intermediary Factor-1 Gamma Autoantibody in Identifying Adult Dermatomyositis Patients with Cancer: A Systematic Review and Meta-analysis.
Best M; Molinari N; Chasset F; Vincent T; Cordel N; Bessis D
Acta Derm Venereol; 2019 Mar; 99(3):256-262. PubMed ID: 30460368
[TBL] [Abstract][Full Text] [Related]
37. Anti-Mi-2 and Anti-TIF1-γ Double-Positive Juvenile Dermatomyositis Treated under Diagnosis of Chronic Eczema: A Case Report.
Yoshida S; Matsumoto H; Fujita Y; Yokose K; Temmoku J; Matsuoka N; Yashiro-Furuya M; Asano T; Sato S; Suzuki E; Yago T; Yaguchi T; Aita T; Kusano M; Yamamoto T; Watanabe H; Migita K
Tohoku J Exp Med; 2022 Apr; 256(4):303-308. PubMed ID: 35296571
[TBL] [Abstract][Full Text] [Related]
38. Splicing factor proline/glutamine-rich is a novel autoantigen of dermatomyositis and associated with anti-melanoma differentiation-associated gene 5 antibody.
Hosono Y; Nakashima R; Serada S; Murakami K; Imura Y; Yoshifuji H; Ohmura K; Naka T; Mimori T
J Autoimmun; 2017 Feb; 77():116-122. PubMed ID: 27919567
[TBL] [Abstract][Full Text] [Related]
39. Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: Experience at a single center in Japan.
Iwata N; Nakaseko H; Kohagura T; Yasuoka R; Abe N; Kawabe S; Sugiura S; Muro Y
Mod Rheumatol; 2019 Sep; 29(5):802-807. PubMed ID: 30092736
[No Abstract] [Full Text] [Related]
40. Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140/MDA5 antibody positive amyopathic dermatomyositis.
Takada T; Aoki A; Asakawa K; Sakagami T; Moriyama H; Narita I; Sato S
Respir Med; 2015 Sep; 109(9):1174-80. PubMed ID: 26187000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
